<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>Treatment of Active TB in Pregnancy</title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>

<body>

<div class="uk-container">
    <div>
        <div class="chapter-header">
            <div class="header-title">
                <div>
                    <img src="ic_chapter.svg" width="16" height="16" class="ic_chapter_icon">
                </div>
                <p class="chapter-title">VI. Pregnancy and TB</p>
            </div>
            <p class="last-updated"><i>Last Updated October 2025</i></p>
        </div>
        <hr>
    </div>
    <p class="uk-paragraph">
        <i><b>TB disease discovered during pregnancy should be treated without delay. </b></i>Because of 
        the risk for tuberculosis to the fetus, treatment of TB in pregnant women should be initiated whenever 
        the probability of maternal disease is moderate to high. A minimum of two sputum samples should be submitted 
        for examination. The outcome of the AFB cultures and drug susceptibility test results will determine the regimen for continuation of treatment.</p>
    <ol>
        <li class="toggle-title" onclick="toggleItem(this)"><span><b>Drug Treatment in
        Pregnancy</b></span><span class="chevron-up">⌃</span></li>
        <div class="item">
        <ul>
            <li>The
        initial treatment regimen usually consists of INH, RIF and EMB; consideration should be given to including PZA.</li>
            <li>Although detailed teratogenicity data are not available, PZA can probably be used safely during pregnancy and is
        recommended for use by the World Health Organization (WHO) and the International Union Against Tuberculosis and
        Lung Disease (IUATLD). In some U.S. jurisdictions, PZA has not been routinely recommended. PZA should be
        included in the initial regimen for HIV seropostive wom- en and for HIV seronegative women who are thought to be
        at high risk for drug resistant TB. If PZA is not includ- ed in the initial treatment regimen, the minimum dura-
        tion of therapy is 9 months.</li>
            <li>Pyridoxine (Vitamin B6) (25 mg/d) is recommended for all pregnant women taking INH.</li>
            <li><i><b>Avoid: </b></i>Aminoglycosides (e.g., streptomycin, amikacin) are contraindicated for all
        pregnant women because of potential adverse effects on the fetus. Fluoroquinolones (e.g., levofloxacin, moxifloxacin) have been associated
        with arthropathies in young animals; therefore, they should be avoided if possible in pregnant women.</li>
        </ul>
        </div>
    <li class="toggle-title" onclick="toggleItem(this)"><span><b>Breast Feeding</b></span><span class="chevron-up">⌃</span></li>
    <div class="item">
    <p>
        The small concentrations of first line TB drugs in breast milk do not have a toxic effect on nursing newborns
        and <b>breast feeding should not be discouraged. </b>Conversely, drugs in breast milk should not be considered
        to serve as effective treatment for disease or as treatment of LTBI in a nursing infant.</p>
        </div>
    </ol>
    <h4 id="table17" class="custom-table-title">Table 17. Use of Anti-TB Medications in Special Situations: Pregnancy, Tuberculous Meningitis
        and Renal Failure</h4>
        <div ID="table_17_use_of_anti-tb_medications_in_special_situations_pregnancy_tuberculosis_meningitis_and_renal_failure" class="uk-overflow-auto">

        <div class="uk-tabs-container">
            <div class="tabs">
            <button class="tab-button active-option" onclick="switchTab(0, event)">Isoniazid</button>
            <button class="tab-button" onclick="switchTab(1, event)">Rifampin</button>
            <button class="tab-button" onclick="switchTab(2, event)">Pyrazinamide</button>
            <button class="tab-button" onclick="switchTab(3, event)">Ethambutol</button>
            <button class="tab-button" onclick="switchTab(4, event)">Aminoglycosides<br>(Streptomycin, Kanamycin, Amikacin)</button>
            <button class="tab-button" onclick="switchTab(5, event)">Capreomycin</button>
            <button class="tab-button" onclick="switchTab(6, event)">Levofloxacin, Moxifloxacin, Gatifloxacin </button>
            <button class="tab-button" onclick="switchTab(7, event)">Ethionamide</button>
            <button class="tab-button" onclick="switchTab(8, event)">Cycloserine</button>
            <button class="tab-button" onclick="switchTab(9, event)">Para-amino-silicylic acid</button>
            <button class="tab-button" onclick="switchTab(10, event)">Clofazimine</button>
        </div>

                
            <div class="tab-content active-option">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th>Safety in Pregnancy</th>
                    <td colspan="2">Safe <span class="info-icon" data-tooltip="NOTE: Supplement with pyridoxine (Vitamin B6) during pregnancy." data-tooltip-position="tooltip-left">i</span></td>
                </tr>
                <tr>
                    <th>Central Nervous System Penetration</th>
                    <td colspan="2">Good (20-100%)</td>
                </tr>
                <tr>
                    <th>Dosage in Renal Insufficiency</th>
                    <td colspan="2">No change</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Safe (isolated reports of malformation)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Fair, Inflamed meninges (10-20%)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>No change</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Caution <span class="info-icon" data-tooltip="NOTE: As with all medications given during pregnancy, anti-TB drugs should be used with caution. The risk of TB to the fetus far outweighs the risk of medications. Pregnant patients with active TB should be treated. Data are limited on the safety of some anti-TB drugs during pregnancy. Table 20 presents a consensus of published data and recommendations. Although detailed teratogenic data is not available, PZA can probably be used safely for pregnant patients. Concentrations of anti-TB drugs in breast milk are low; treatment with these medications is not a contraindication to breastfeeding. (Conversely, medication present in breast milk is not sufficient to prevent or treat TB in the newborn.) Consult a medical expert when treating a pregnant patient who has TB. For treatment of LTBI, most authorities recommend beginning INH several months after delivery, unless the woman is at high risk for progression to active TB (e.g., recent TST or IGRA conversion, HIV-infected)." data-tooltip-position="tooltip-left">i</span></td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Good (75-100%)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>Decrease dose/ Increase interval</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Safe</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Inflamed meninges only (4-64%)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>Decrease dose/ Increase interval</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Avoid</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Poor <span class="info-icon" data-tooltip="NOTE: Has been used intrathecally; efficacy not documented." data-tooltip-position="tooltip-left">i</span></td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>Decrease dose/ Increase interval <span class="info-icon" data-tooltip="NOTE: Avoid aminoglycosides and capreomycin in patients with reversible renal damage, if possible." data-tooltip-position="tooltip-left">i</span></td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Avoid</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Poor</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>Decrease dose/ Increase interval <span class="info-icon" data-tooltip="NOTE: Avoid aminoglycosides and capreomycin in patients with reversible renal damage, if possible." data-tooltip-position="tooltip-left">i</span></td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Do not use</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Fair (5-10%) Inflamed meninges (50-90%)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>Decrease dose/ Increase interval <span class="info-icon" data-tooltip="NOTE: Fluoroquinolones may accumulate in renal failure and are poorly removed by dialysis. Dose adjustment indicated." data-tooltip-position="tooltip-left">i</span></td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Avoid</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Good (100%)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>No change</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Avoid</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Good (50-100%)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>Decrease dose/ Increase interval</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Safe</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Inflamed meninges only (50-100%)</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>Incomplete data</td>
                </tr>
                </tbody>
            </table>
        </div>

        <div class="tab-content">
            <table class="uk-table uk-table-small uk-table-divider">
                <tbody>
                <tr>
                    <th class="uk-text-nowrap">Safety in Pregnancy</th>
                    <td>Avoid</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Central Nervous System Penetration</th>
                    <td>Unknown</td>
                </tr>
                <tr>
                    <th class="uk-text-nowrap">Dosage in Renal Insufficiency</th>
                    <td>Probably no change</td>
                </tr>
                </tbody>
            </table>
        </div>

        <ul>
            <li>Safe: Drug has not been demonstrated to have teratogenic effects.</li>
            <li>Avoid: Limited data on safety or for aminoglycosides associated with hearing impairment and/or other toxicity.</li>
            <li>Do Not Use: Associated with premature labor, congenital malformations or teratogenicity.</li>
        </ul>
</div>
</body>

<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/script.js" type="text/javascript"></script>
<script src="main.js" type="text/javascript"></script>
<script>
// Initialize the first tab as active
document.addEventListener('DOMContentLoaded', function() {
    const tableContainer = document.getElementById('table_17_use_of_anti-tb_medications_in_special_situations_pregnancy_tuberculosis_meningitis_and_renal_failure');
    activateTab(tableContainer, 0);
});

document.addEventListener("DOMContentLoaded", function () {
const tooltips = document.querySelectorAll(".info-icon");

document.addEventListener("click", function (event) {
    if (!event.target.closest(".info-icon")) {
        document
        .querySelectorAll(".info-icon.active")
        .forEach((activeIcon) => {
            activeIcon.classList.remove("active");
        });
    }
    });

    tooltips.forEach(function (icon) {
    let tooltip = icon.querySelector(".tooltip");
    if (!tooltip) {
        tooltip = document.createElement("div");
        tooltip.className = "tooltip";
        tooltip.textContent =
        icon.getAttribute("data-tooltip") || "Additional information";

        // Get positioning class from data attribute
        const positionClass =
        icon.getAttribute("data-tooltip-position") || "tooltip-center";
        tooltip.classList.add(positionClass);

        icon.appendChild(tooltip);
    }

    let isTooltipVisible = false;

    icon.addEventListener("click", function (event) {
        event.stopPropagation();

        document
        .querySelectorAll(".info-icon.active")
        .forEach((activeIcon) => {
            if (activeIcon !== icon) {
            activeIcon.classList.remove("active");
            const otherTooltip = activeIcon.querySelector(".tooltip");
            if (otherTooltip) otherTooltip.style.display = "none";
            }
        });

        isTooltipVisible = !this.classList.contains("active");
        this.classList.toggle("active");
        tooltip.style.display = isTooltipVisible ? "block" : "none";
    });
    });
});
  
</script>
</html>
